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Abstract
Introduction: Impaired proliferation and production of IL2 are the hallmarks of
experimental T cell tolerance. However, in most autoimmune diseases, auto-
reactive T cells do not display hyper proliferation, but inflammatory phenotypes.
Methods:We have now demonstrated that the transcription factors Egr2 and 3 are
important for the control of inflammatory cytokine production by tolerant T cells,
but not for tolerance induction.
Results: In the absence of Egr2 and 3, T cell tolerance, as measured by impaired
proliferation and production of IL2, can still be induced, but tolerant T cells
produced high levels of inflammatory cytokines. Egr2 and 3 regulate expression of
differentiation repressors and directly inhibit T-bet function in T cells. Indeed,
decreased expression of differentiation repressors, such as Id3 and Tcf1, and
increased expression of inflammatory transcription factors, such as RORgt and
Bhlhe40 were found in Egr2/3 deficient T cells under tolerogenic conditions. In
addition, T-bet was co-expressed with Egr2 in tolerant T cells and Egr2/3 defects
leads to production of high levels of IFNg in tolerant T cells.
Conclusions: Our findings demonstrated that despite impaired proliferation and
IL2 production, tolerant T cells can display inflammatory responses in response to
antigen stimulation and this is controlled at least partly by Egr2 and 3.
Introduction
Tolerance to self-antigens is an important function of
peripheral T cells. In homeostatic conditions, self-tolerance
of T cells is controlled by extrinsic mechanisms such as
regulatory T (Treg) cells [1] and also intrinsic mechanisms
induced by suboptimal stimulation of T cell receptors (TCR)
in response to self-antigens [2]. In optimal immune
responses against pathogen infection, proliferation and
production of IL2 are essential for clonal expansion of
antigen specific T cells, which is coupled with differentiation
and acquisition of effector function [3]. Under tolerogenic
conditions, the TCR signaling pathway is only partially
activated rendering T cells unable to express IL2 and cell
cycle regulatory molecules [2]. Therefore, the hallmarks of
tolerant T cells are impaired proliferation and production of
IL2 [2]. However, although hypoproliferation and reduced
production of IL2 in response to antigen stimulation are the
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hallmarks of T cell tolerance, auto-reactive T cells from
autoimmune disease patients rarely display hyperprolifera-
tion in response to autoantigens. On the contrary, T cells
from autoimmune disease patients often show dysfunctional
responses to TCR stimulation with defects in proliferation
and production of IL2 [4, 5]. Despite impaired proliferation,
the autoreactive T cells from these patients are generally
hyperactivated and inflammatory [4, 5], indicating that self-
tolerance is not limited to the control of proliferation and
production of IL2, but also requires control of the
inflammatory differentiation of effector T cells [6].
Egr2 and 3 are transcription factors induced in tolerant T
cells in response to TCR stimulation [7–9]. T cell-specific
deficiency of Egr2 and 3 leads to loss of self-tolerance and the
development of severe autoimmune symptoms [10–12].
Interestingly, although CD2-specific Egr2 and 3 deficient
mice developed severe systemic autoimmune syndromes,
Egr2 and 3 deficiency does not enhance TCR mediated
proliferation. In contrast, Egr2 and 3 deficient T cells
proliferated poorly and were defective in IL2 production in
response to TCR stimulation [11]. Thus, Egr2 and 3 are not
inhibitors of TCRmediated proliferation, but promote T cell
proliferation. Importantly, these findings demonstrated that
autoimmune responses do not necessarily require hyper-
proliferation and excessive production of IL2 by autoreactive
T cells, but can result from hyper-activation and inflamma-
tory responses, which resemble the dysfunctional T cells in
autoimmune diseases such as lupus [4, 5].
To investigate the function of Egr2 and 3 in tolerant T
cells, we assessed the role of Egr2 and 3 in the development of
T cell tolerance in vitro and in vivo. Tolerance, as measured
by impaired proliferation and IL2 production, can be
induced in Egr2 and 3 deficient T cells. However, despite
proliferative tolerance, Egr2 and 3 deficient tolerant T cells
expressed high levels of CD44 and CD69, and produced high
levels of inflammatory cytokines in response to antigen
stimulation. We found that together with Egr2, T-bet was
also induced in tolerant T cells indicating a repressive effect
of Egr2 and 3 on T-bet function in tolerant as well as effector
T cells [13]. We also found that Egr2 and 3 controlled
regulators of differentiation [14] are defective in tolerant T
cells from CD2-specific Egr2 and 3 deficient mice. Our
findings not only defined the role of Egr2 and 3 in tolerant T
cells, but also revealed a novel tolerance mechanism that
inhibits the effector function of tolerant T cells.
Experimental Procedures
Mice
CD2-Egr2/3/ (CD2-Cre/Egr2loxp/loxp/Egr3/) and GFP-
Egr2 knockin mice were reported previously [11, 14].
C57BL/6 mice purchased from Charles River were used as
controls in all experiments. All mice analyzed were 7–8 weeks
of age. No animal was excluded from the analysis, and the
number of mice used was consistent with previous experi-
ments using similar experimental designs. All mice were
maintained in the Biological Services Unit, Brunel Univer-
sity, and used according to established institutional guide-
lines under the authority of a UK Home Office project
license.
Antibodies and flow cytometry
Fluorescein isothiocyanate (FITC)-conjugated antibodies to
CD4 (cat 11-0041-81, clone GK1.5), CD45.1 (cat 11-0453-
81, clone A20), and IFNg (cat 11-7311-81, clone XMG1.2);
phycoerythrin (PE)-conjugated antibodies to CD3 (cat 12-
0031-81, clone 145-2C11), CD4 (cat 12-0041-81, clone
GK1.5), CD25 (cat 12-0251-81, clone PC61.5), CD62L (cat
12-0621-81, clone MEL-14), CD69 (cat 12-0691-81, clone
H1.2F3), and Egr2 (cat 12-6691-80, clone erongr2); PerCP-
Cy5.5 labeled antibodies to CD3 (cat 45-0031-80, clone 145-
2C11) and CD45.2 (cat 45-0454-80, clone 104); allophyco-
cyanin (APC)-conjugated antibodies to CD44 (cat 17-0441-
81, clone IM7), CD3 (cat 17-0031-81, clone 145-2C11), Egr2
(cat 17-6691-82, clone erongr2); and PEcy7-conjugated
antibodies to CD44 (cat 25-0441-81, clone IM7) and
T-bet (cat 25-5825-82, clone 4B10) were obtained from
E-bioscience. FITC or PE labeled antibodies to TCRVb3
(clone KJ25, cats: 553208 and 553209) were purchased from
BD Biosciences. Antibodies to CD3 (cat 557306, clone 145-
2C11) and CD28 (cat 557393, clone 37.51) for stimulation
and 7AAD were obtained from BD Biosciences. For flow
cytometry analysis, single cell suspensions were analyzed on
a LSRII or Canto (BD Immunocytometry Systems) and the
data were analyzed using FlowJo (Tree Star). Cell sorting was
performed on a FACSAria sorter with DIVA option (BD
Immunocytometry Systems).
Cell isolation and stimulation
Na€ıve CD4þ T cells were purified by negative selection using
a MACS system (Miltenyi Biotec) or isolated by sorting
CD25CD4þCD44highCD62L and
CD25CD4þCD44lowCD62Lþ T cells by FACS. Cells were
gated on CD25- cells to exclude activated cells and Treg.
Purified CD4þ T cells were stimulated with plate-bound
anti-CD3 at 1mg/mL, or at the indicated concentrations,
together with anti-CD28 (2mg/mL) antibodies. For analysis
of Egr2 and T-bet expression, the cells were processed using
the Foxp3 staining kit (E-bioscience). For analysis of
cytokine producing cells, the cells were stimulated with
50 ng/mL PMA and 200 ng/mL Ionomycin in the presence of
Golgistop (BD) for 4 h before analysis of cytokine producing
cells by flow cytometry.
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Anergy induction
Na€ıve CD4 T cells were stimulated with 1mg/mL anti-CD3
for 24 h. The cells were then washed with PBS and rested for
24 h in fresh medium. After resting, cells were recounted and
re-stimulated using plates coated with anti-CD3 (at 1mg/mL
or the indicated concentrations) and anti-CD28 (2mg/mL).
Proliferation
For in vitro anergy, 2 105 cells/well were re-stimulated
with anti-CD3 at the indicated concentrations and anti-
CD28 (2mg/mL) in triplicate for 3 days. For SEA responding
T cells, isolated CD4þTCRVb3þ cells were incubated with
SEA loaded congenic DC cells at a 1:1 ratio in 96-well plates
in triplicate for 3 days. A total of 1mCi of [3H]TdR was
added for the last 8 h of culture, the cells were then harvested
and subjected to scintillation counting to measure [3H]TdR
incorporation.
ELISA
The concentrations of IL2 and IFNg in the cell culture
supernatants were measured using ELISA kits (R & D)
according to the manufacturer’s instructions.
SEA activation and tolerance
Ten micrograms of Staphylococcal enterotoxin A (SEA,
Sigma–Aldrich) in 0.2mL of phosphate-buffered saline with
1% normal congenic serum were injected intravenously (i.v.)
at 4 day intervals. SEA was injected five times to induce
tolerance and once to induce T cell activation [15]. Twenty-
four hours after the last injection, CD4þTCRVb3þ cells were
isolated by FACS and stimulated with SEA loaded dentritic
cells (DC) at a 1:1 ratio in vitro. The SEA loaded DCs were
prepared as follows: splenic CD11cþ cells fromwild-typemice
were isolated by MACS and cultured in the presence of
10 ng/mL GM-CSF (R & D) for 48 h to induce DC cell
maturation. Mitomycin C (Sigma–Aldrich) at 50mg/mL was
added for the last 30min of culture. DCs were washed and
loaded with SEA by incubation with SEA at 200 ng/mL for
30min. Unbound SEA was removed by washing and loaded
DCswereused to stimulateCD4þTCRVb3þ cells at a 1:1 ratio.
Quantitative real-time PCR
Total RNA was extracted from cells using Trizol (Invitrogen)
and reverse transcribed using random primers (Invitrogen).
Quantitative real-time PCR was performed on a Rotor-Gene
system (Corbett Robotics) using SYBR green PCR master mix
(Qiagen). The primers used are as follows: Egr2: sense 50-CTT
CAGCCGAAGTGACCACC-30 and antisense 50-GCTCTTCC
GTTCCTTCTGCC-30; Egr3: sense 50-GCTCTTCCGTTCCTT
CTGCC-30 and antisense 50-CGGTGTGAAAGGGTGGAAAT-
30; IL2: sense 50-GCATGTTCTGGATTTGACTC-30 and anti-
sense 50-CAGTTGCTGACTCATCATCG-30; IFNg: sense 50-
CCATCAGCAACAACATAAGC-30 and antisense 50-AGCTC
ATTGAATGCTTGGCG-30; Id3: sense 50-ACATGAACCACT
GCTACTCGC-30 and antisense 50-TGAGCTCAGCTGTCTG
GATCG-30; Tcf1: sense 50-CCCAGCTTTCTCCACTCTACG-
30 and antisense 50-CTGTGAACTCCTTGCTTCTGGC-30;
Bhlhe40: sense 50-ACGTTGAAGCACGTGAAAGC-30 and
antisense 50-GAAGTACCTCACGGGCACAA-30; RORgt sense
50-TGAGGCCATTCAGTATGTGG-30 and antisense 50-CTTC
CATTGCTCCTGCTTTC-30; IL17: sense 50-AGCGTGTCCAA
ACACTGAGG-30 and antisense 50-CTATCAGGGTCTTCA
TTGCG-30; GAPDH: sense 50-TGCACCACCAACTGCTTA
GC-30 and antisense 50-GGCATGGACTGTGGTCATGAG-30;
IL6: sense 50-TGGTCTTCTGGAGTACCATAGC-30 and anti-
sense 50-ACTCCTTCTGTGACTCCAGC-30; GM-CSF: sense
50-TGGTCTACAGCCTCTCAGCA-30 and antisense 50-CCGT
GACCCTGCTCGAATA-30.
The data were analyzed using the Rotor-Gene Software.
All samples were run in triplicate, and relative mRNA
expression levels were obtained by normalizing against the
level of Gapdh from the same sample under the same
program using: relative expression¼ 2(CTgapdhCTtarget).
Bone marrow chimeras
Bonemarrowwas collected fromCD2-Egr2/3/ (CD45.2þ)
or wild-type C57BL/6 (CD45.1þ) mice. For each chimera,
20 106 cells of a 1:1mixture of CD2-Egr2/3/ and C57BL/
6 bone marrow cells were transferred intravenously into
lethally irradiated (two doses of 550 rads) wild-type C57BL/6
(CD45.1þ) recipients. Recipient mice were allowed 6–8
weeks for reconstitution.
Statistics
To analyze the statistical significance of differences between
groups, Kruskal–Wallis tests followed by pairwise compar-
isons using Conover tests, as implemented in the R package
PMCMR [16], with Benjamini–Hochberg correction
for multiple comparisons were used. Differences with a
p-value< 0.05 were considered significant.
Results
Egr2 and 3 are not required to induce tolerance in
T cells
Egr2 and 3 have been discovered in tolerant T cells induced
in vivo by persistent antigen stimulation and in vitro by
suboptimal T cell receptor stimulation [7, 8]. It has been
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previously suggested that they play a role in the induction
of T cell tolerance in vitro [8]. However, in response to
viral infection, Egr2 and 3 in T cells have been found to
promote antigen induced proliferation [14]. To assess
whether Egr2 and 3 have a role in induction of T cell
tolerance, TCRVb3þCD4þ cells from wild-type and CD2-
specific Egr2/3/ mice were analyzed after repeated
administration of the super-antigen Staphylococcal en-
terotoxin A (SEA); a well-established model for induction
of T cell tolerance in vivo [15]. In na€ıve mice, the
proportions of TCRVb3þ cells among the CD4þ popula-
tion were similar in wild-type and CD2-specific Egr2/3/
mice (Fig. 1A). SEA mediated activation of
TCRVb3þCD4þ T cells was analyzed in mice following a
single injection of SEA. TCRVb3þCD4þ T cells from wild-
type mice that received a single administration of SEA
proliferated and produced IL2 in response to re-challenge
in vitro (Fig. 1B and C), while the proliferation and IL2
production of TCRVb3þCD4þ T cells from SEA chal-
lenged CD2-specific Egr2/3/ mice were reduced in
response to SEA in vitro (Fig. 1B and C), consistent with
previous findings [14]. Repeated SEA stimulation induced
tolerance of Vb3þCD4þ T cells in wild-type mice
(Fig. 1B and C), consistent with previous findings [15],
and Egr2 and 3 were induced in both activated and tolerant
T cells in response to SEA stimulation (Fig. 1D and E).
Similar to wild-type mice, Vb3þCD4þ T cells in CD2-
specific Egr2/3/ mice were also rendered tolerant by
repeated administration of SEA (Fig. 1B and C). Crucially,
despite the induction of tolerance, the tolerant Vb3þCD4þ
T cells from CD2-specific Egr2/3/ mice were highly
activated with high levels of CD25, CD44, and CD69
(Fig. 1F). These results demonstrate that Egr2 and 3 are not
required for the TCR mediated induction of proliferative
tolerance, but are important for controlling the activation
of tolerant T cells.
The induction of T cell anergy in Egr2 and 3 deficient CD4
T cells was also analyzed in vitro by suboptimal T cell
receptor stimulation in the absence of co-stimulation. In
addition to the impaired proliferative responses and IL2
production by Egr2 and 3 deficient T cells in response to
optimal stimulation (Fig. 2A), consistent with our previous
findings [11], anergy was effectively induced in Egr2 and 3
deficient CD4 T cells by stimulation with anti-CD3 alone
(Fig. 2A), indicating that although Egr2 and 3 are induced in
both activated and tolerant T cells (Fig. 2B), they are not
required for the induction of proliferative tolerance in vitro.
In accordance with the over-activation of Egr2 and 3
deficient tolerant T cells in vivo (Fig. 1F), Egr2/3 deficient
anergic CD4 T cells were hyper-activated as indicated by
high levels of CD44 and CD69 (Fig 2C). Thus, Egr2 and 3 are
not required for the development of T cell tolerance, but for
controlling the activation of tolerant T cells.
Egr2 and 3 are essential for the control
of inflammatory responses of tolerant T cells
One of the major functions of Egr2 and 3 in T cells is to
control the inflammatory responses of effector T cells
[10–14]. Although impaired proliferation and IL2 produc-
tion are the hallmarks of tolerant T cells, the effector
function of tolerant T cells has not been analyzed. We
assessed the effector function of tolerant CD4 T cells from
wild-type and CD2-specific Egr2/3/ mice by analysis of
IFNg production, a cytokine commonly produced by
effector CD4 T cells. Compared to high levels of IFNg
production by Vb3þCD4þ cells from SEA activated wild-
type and CD2-specific Egr2/3/mice, the IFNg production
in Vb3þCD4þ cells from SEA tolerant wild-type mice was
significantly reduced (Fig. 3A and B). However, despite
tolerance of proliferation and IL2 production, Vb3þCD4þ
cells from SEA tolerant CD2-specific Egr2/3/ mice
produced high levels of IFNg (Fig. 3A and B). In addition
to IFNg, IL6, IL17, and GM-CSF were also expressed in SEA
tolerant Egr2/3 deficient CD4 T cells (Fig. 3C), indicating
that Egr2 and 3 are not involved in induction of tolerance,
but are important to control activation and effector function
of tolerant T cells. A high level of IFNg production was also
detected in anergic CD4 T cells from CD2-specific Egr2/3/
mice induced by suboptimal TCR stimulation (Fig. 4A and
B).
To further investigate the association between the levels of
Egr2 expression and IFNg production, T cells were
stimulated with different doses of anti-CD3 with or without
anti-CD28 and Egr2 expression and IFNg producing T cells
were analyzed. Dose dependent Egr2 expression in wild-type
T cells corresponded well to the dose dependent proportion
of IFNg producing T cells among Egr2/3/ T cells (Fig. 4C),
which further support the notion that Egr2 and 3 are
important for controlling inflammatory responses in both
optimal and suboptimal TCR stimulation. Taken together,
these data indicate that although Egr2 and 3 are not required
for the induction of proliferative tolerance, they are
important for tolerance of effector function.
Egr2 and 3 intrinsically control inflammatory, but
not proliferative, responses of tolerant T cells
To exclude the possibility of environmental factors affecting
tolerance induction in CD2-Egr2/3/mice, irradiated wild-
type mice were reconstituted with a mixture of bone marrow
from wild-type and CD2-Egr2/3/ mice (Fig. 5A) as
described previously [14]. In vivo T cell tolerance was
induced in these chimeras by repeated SEA administration.
Wild-type TCRVb3þCD4þ cells in the chimeras displayed
proliferative and inflammatory tolerance after tolerogenic
treatment with SEA (Fig. 5B–F). Consistent with the
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results from CD2-Egr2/3/ mice, Egr2/3 deficient
TCRVb3þCD4þ cells in the chimeras also displayed similar
impairments in proliferation and IL2 production (Fig. 5B and
C), but expressed high levels of activation markers and
produced excessive levels of inflammatory cytokines such as
IFNg (Fig. 5D–F). These results demonstrated that Egr2 and 3
intrinsically control the inflammatory responses, but not
proliferation, of tolerant T cells.
Figure 1. Egr2 and 3 are important for the control of the activation of tolerant T cells, but are not required for the induction of proliferative tolerance in
vivo. (A) Egr2 and TCRVb3 were analyzed on gated CD4 T cells from naive wild-type (WT) and CD2-Egr2/3/ (Egr2/3/) mice. (B–F) Wild-type and CD2-
Egr2/3/micewere injectedwith SEA once to activate T cells (Act) orﬁve timeswith 4 day intervals to induce tolerance (Tol) and analyzed24h after the last
injection. (B and C) TCRVb3þCD4þ T cells were isolated and re-stimulated in vitro with SEA loaded dendritic cells. Three days after re-stimulation,
proliferation (B) and IL2 in supernatants (C) were measured. (D and E) Expression of Egr2 and 3 in isolated TCRVb3þCD4þ T cells was measured by RT-PCR
using the ddCtmethodwithGAPDHas a referencegene.Data shownare themean s.d. (F) Phenotypingof gatedCD3þCD4þTCRVb3þ cells. Data inA,D,
E, F are from cells isolated from spleens and lymph nodes pooled from four mice in each group and are representative of three independent experiments.
Data in B and C are from ﬁvemice in each group and are representative of three independent experiments. Data in B and C are themean s.e.m. andwere
analyzed with Kruskal–Wallis tests followed by Conover tests with Benjamini–Hochberg correction. N.S. not signiﬁcant, p< 0.05, p< 0.01.
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Egr2 and 3 regulate inflammatory repressors and
the function of T-bet in tolerant T cells
T cell tolerance is defined experimentally by impaired
proliferation and production of IL2 in response to antigen
stimulation [2]. Although Egr2 and 3 are induced in tolerant
T cells by antigen stimulation [7, 8], their function in effector
T cells is to promote antigen mediated proliferation, but
suppress inflammatory differentiation [11, 14]. The mecha-
nisms of Egr2 and 3 function in the control of effector T cells
Figure 2. Egr2 and 3 are not required for the induction of T cell anergy, but control the activation of anergic T cells in vitro. (A) Na€ıve CD4 T cells
(CD62LþCD44lo) from wild-type (WT) and CD2-Egr2/3/ (Egr2/3/) mice were stimulated with anti-CD3 alone for 24 h, then washed and rested for
24 h before re-stimulation with anti-CD3 and anti-CD28 (Tol). Proliferation (top panels) and IL2 production (bottom panels) were measured after 3 days
and 24h, respectively, and compared to activated T cells (Act). (B) Egr2 and 3 expression in naive, activated and tolerant T cells was measured by RT-PCR
using the ddCt methodwith GAPDH as a reference gene. Data shown are the mean s.d. (C) CD44 and CD69 expression on na€ıve CD4 T cells that were
treated for 24 h with PBS (Naive), anti-CD3 and anti-CD28 (Act), or anti-CD3 alone (Tol) was analyzed. Data are representative of three independent
experiments.
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in adaptive immunity are to regulate the expression of
inflammatory repressors and to directly inhibit the function
of T-bet [13, 14]. To investigate the mechanisms of Egr2 and
3 function in the control of inflammatory responses of
tolerant T cells, anergy was induced in na€ıve CD4 T cells
from wild-type and CD2-Egr2/3/ mice in vitro and the
expression of repressors of effector differentiation (Id3 and
Tcf1, encoded by the Tcf7 gene) regulated by Egr2 and 3 [14]
was analyzed. Indeed, consistent with the high levels of
inflammatory cytokines, the expression of repressors of T
cell differentiation was significantly reduced in Egr2/3/
tolerant T cells (Fig. 6). In contrast, transcription factors
involved in differentiation (Bhlhe40 and RORgt, encoded by
the Rorc gene) were increased (Fig. 6). The altered expression
of transcription factors that regulate inflammation was
associated with impaired IL2 and increased IFNg and IL17
expression in Egr2/3/ tolerant T cells (Fig. 6). Impor-
tantly, FoxP3 expression in wild-type and Egr2/3/
tolerant T cells was similar (Fig. 6), indicating that these
differences are not due to defective FoxP3 expression
consistent with our previous findings [11]. These results
demonstrate that Egr2 and 3 function via similar mecha-
nisms to inhibit inflammatory responses of effector [14] and
tolerant T cells.
We previously found that Egr2 can directly inhibit T-bet
function [13]. However, whether T-bet is induced in tolerant
T cells in response to TCR stimulation is unknown. We
discovered that T-bet was induced in both activated and
anergic wild-type T cells and T-bet was co-expressed with
Egr2 (Fig. 7A). Moreover, T-bet was highly induced in both
activated and anergic Egr2/3 deficient T cells (Fig. 7A).
Similarly, co-expression of Egr2 and T-bet was detected in
TCRVb3þCD4þ cells from GFP-Egr2 knockin mice follow-
ing activating or tolerizing treatment with SEA in vivo
(Fig. 7B). Thus, consistent with the inhibitory effect of Egr2
and 3 on T-bet function in adaptive immune responses [13],
Egr2 and 3 may control T-bet function in tolerant T cells.
Discussion
Effector phenotype T cells with high levels of activation
markers such as CD44 accumulate during homeostatic
responses [17, 18]. However, these cells maintain their
tolerance to self-antigens which is regulated by both extrinsic
and intrinsic mechanisms [19, 20]. Two experimental
systems have been established for investigation of T cell
tolerance, T cell anergy induced by suboptimal TCR
stimulation in vitro [2] and T cell tolerance induced by
Figure 3. Deﬁciency of Egr2 and 3 results in production of inﬂammatory cytokines by tolerant T cells in vivo. Wild-type (WT) and CD2-Egr2/3/
(Egr2/3/) mice were injected with SEA once to activate T cells (Act) or ﬁve times with 4 day intervals to induce tolerance (Tol). Twenty-four hours after
the last injection, CD3þCD4þTCRVb3þ cells were isolated and re-stimulated in vitro with SEA loaded dendritic cells for 24 h. Supernatants were analyzed
for IFNg by ELISA (A) and IFNg producing cells were quantiﬁed (B). Expression of GM-CSF (encoded by Csf2), IL6 and IL17 in sorted CD3þCD4þTCRVb3þ
cells were analyzed by RT-PCR using the ddCtmethodwith GAPDH as a reference gene (C). Data are from ﬁve mice in each group and are representative
of three experiments. Data in A and C are the mean s.e.m. and were analyzed with Kruskal–Wallis tests followed by Conover tests with Benjamini–
Hochberg correction. N.S. not signiﬁcant, p< 0.05, p< 0.01.
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Figure 4. Egr2 and 3 are important to control inﬂammatory cytokine production by tolerant T cells. (A) Na€ıveCD4 T cells (CD62LþCD44lo) fromwild-type
(WT) andCD2-Egr2/3/ (Egr2/3/) micewere stimulatedwith anti-CD3 alone for 24 h, thenwashed and rested for 24 h before re-stimulationwith anti-
CD3 and anti-CD28 (Tol). IFNg production was measured after 24 h and compared to na€ıve and activated T cells (Act). (B) After re-stimulation, a
proportion of tolerant T cells were treated with PMA and Ionomycin in the presence of Golgistop for 4 h and IFNg producing cells were quantiﬁed. (C)
Na€ıve CD4 T cells were isolated and stimulated with the indicated stimuli for 24 h and Egr2 (top) and IFNg (bottom) expressing cells were analyzed. Data
are representative of three independent experiments. Data in A are the mean s.e.m. and were analyzed with Kruskal–Wallis tests followed by Conover
tests with Benjamini–Hochberg correction. N.S. not signiﬁcant, p< 0.05, p< 0.01.
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Figure 5. Egr2/3 intrinsically control inﬂammatory activation of tolerant T cells in vivo. An equal number of bone marrow cells from wild-type (WT) and
CD2-Egr2/3/ (Egr2/3/) mice were adoptively transferred into irradiated wild-type recipients. Six weeks after bone marrow reconstitution, wild-type
(CD45.1) and Egr2/3/ (CD45.2) cells among gated CD4þTCRVb3þ cells were quantiﬁed (A). Recipient mice were injected with SEA once to activate T
cells (Act) or ﬁve times with 4 day intervals to induce tolerance (Tol). Twenty-four hours after the last injection, CD4þTCRVb3þCD45.1þ (WT) and
CD4þTCRVb3þCD45.2þ (Egr2/3/) cells were isolated and re-stimulated with SEA loaded dendritic cells in vitro. (B) Proliferation was measured 3 days
after re-stimulation. (C) IL2 in supernatants was measured by ELISA 24 h after re-stimulation. (D) CD62L and CD44 expression on gated
CD4þTCRVb3þCD45.1þ (WT) and CD4þTCRVb3þCD45.2þ (Egr2/3/) cells from recipient mice was analyzed 24 h after the last SEA injection. (E and F)
IFNg producing cells among gated CD4þTCRVb3þ cells were analyzed after re-stimulation for 24 h. Data in A, D, E are from ﬁve mice in each group and
are representative of two experiments. Data in B, C and F are from ﬁvemice for each group and are representative of two experiments. Data in B, C, and F
are the mean s.e.m. and were analyzed with Kruskal–Wallis tests followed by Conover tests with Benjamini–Hochberg correction. N.S. not signiﬁcant,
p< 0.05, p< 0.01.
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repetitive stimulation with high affinity antigens in vivo [7,
21]. The hallmarks of tolerance in both systems are impaired
proliferation and IL2 production in response to antigen
stimulation [2, 7, 21]. Egr2 and 3 were initially discovered in
tolerant T cells following antigen stimulation in vitro and in
vivo [7, 8] and were suggested to negatively regulate the
activation of T cells [9]. However, recent findings demon-
strate that Egr2 and/or 3 are not inhibitors, but promoters, of
TCR mediated proliferation and IL2 production [11, 14].
Here, we demonstrated a novel function of Egr2 and 3 in
tolerant T cells: suppressing inflammatory responses.
Although impaired proliferation and production of IL2 in
response to antigen stimulation are the hallmarks of T cell
tolerance, in many, if not all, autoimmune diseases, T cells
are hyper-activated and display unwanted effector function,
but their proliferation and production of IL2 are
impaired [4]. This phenotype is associated with defects in
TCR signaling [4], suggesting that impaired TCR signaling
cannot drive cell cycle progression, but can still induce
activation and effector function of tolerant T cells. The
increased inflammatory activation, yet impaired prolifera-
tion, of Egr2/3/ tolerant T cells demonstrates that the
development of effector function may not be controlled by
same mechanisms that control cell cycle progression and
production of IL2, and that the effector function of tolerant
T cells is controlled at least partly by Egr2 and 3.
In contrast to the impaired induction of AP1 and NFkB in
tolerant T cells [2, 7, 21], transcription factors important for
regulating the differentiation of effector T cells were induced
by TCR stimulation in both activated and tolerant T cells.
Egr2 and 3 are important regulators that control expression
of inflammatory transcription factors, such as RORgt and
Figure 6. Transcription factors regulated by Egr2 and 3 during immune responses are altered in Egr2/3 deﬁcient tolerant T cells. Na€ıve CD4 T cells
(CD62LþCD44lo) from wild-type (WT) and CD2-Egr2/3/ (Egr2/3/) mice were stimulated with anti-CD3 alone for 24 h, then washed and rested for
24 h before re-stimulationwith anti-CD3 and anti-CD28 (Tol). After 24 h expression of transcription factors and cytokineswas analyzed and compared to
na€ıve and activated T cells (Act). Data were analyzed using the ddCt method with GAPDH as a reference gene and are representative of three
independent experiments. Data are themean s.e.m. andwere analyzedwith Kruskal–Wallis tests followed by Conover tests with Benjamini–Hochberg
correction. N.S. not signiﬁcant, p< 0.05, p< 0.01.
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Bhlhe40, while inducing expression of repressors of
inflammatory differentiation, such as Tcf1 and Id3, in
effector T cells [14]. Deficiency of Egr2 and 3 leads to altered
expression of these transcription factors and severe
inflammatory pathology during viral infection [14]. We
have now demonstrated that the Egr2/3 regulatory pathway
is also important to control inflammatory responses of
tolerant T cells by a similar mechanism. Thus, deficiency in
Egr2 and 3 does not prevent the induction of proliferative
tolerance, but causes tolerant T cells to become activated and
produce inflammatory cytokines, a phenotype resembling
effector T cells from autoimmune diseases such as lupus [4].
Th1 inflammatory responses are a major mechanism in
most autoimmune diseases and T-bet plays an important role
in Th1 type autoimmune responses [22, 23]. Despite the
evidence of increased T-bet function in autoimmunity, the
mechanism leading to inappropriate T-bet mediated Th1
responses in these autoimmune conditions is unknown. We
have recently discovered that Egr2 can directly inhibit T-bet
function in effectorT cells [13] andhave now found thatT-bet
is expressed in tolerant T cells. The expression of T-bet in
tolerant T cells indicates that although the TCR mediated
biochemical signals are insufficient for inducing T cells to
enter the cell cycle, the signal is enough to induce expressionof
Figure 7. T-bet is co-expressed with Egr2 in tolerant T cells. (A) Na€ıve CD4 T cells (CD62LþCD44lo) from wild-type (WT) and CD2-Egr2/3/ (Egr2/3/)
mice were stimulated with anti-CD3 alone for 24 h, thenwashed and rested for 24 h before re-stimulationwith anti-CD3 and anti-CD28 (Tol). After 24 h
expression of T-bet and Egr2 was analyzed and compared to na€ıve and activated T cells (Act). (B) GFP-Egr2 knockin and CD2-Egr2/3/ mice were
injected with SEA once to activate T cells (Act) or ﬁve times with 4 day intervals to induce tolerance (Tol). Twenty-four hours after the last injection,
CD3þCD4þTCRVb3þ cells were analyzed for T-bet and Egr2 expression. Data in A are from pooled cells of three mice and are representative of three
experiments. Data in B are from four mice in each group and are representative of two experiments.
B. Omodho et al. Egr2 and 3 control effector function of tolerant T cells
© 2018 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 231
T-bet. T-bet in tolerant T cells is co-expressed with Egr2 and
defects inEgr2 and3 leads tohigh levels of IFNgproduction in
tolerant T cells. These results demonstrate the importance of
inhibition of T-bet by Egr2 and 3 [13] in tolerant T cells and
suggest that Egr2 and 3 control Th1-like inflammatory
responses in homeostatic conditions, which may be an
important mechanism for the control of autoimmunity.
Recently, conflicting findings on the role of Egr2 and 3 in
regulation of T cell proliferation have been reported [8, 9,
11]. The findings that Egr2 is induced in tolerant T cells and
forced Egr2 expression leads to inhibition of proliferation in
vitro after TCR stimulation suggest a function of Egr2 in the
induction of proliferative tolerance [9]. However, it has been
reported that forced expression of Egr2 in cell lines of many
tissue types results in growth inhibition [24], which indicates
an artificial effect of Egr2 overexpression. In contrast,
peripheral T cells from Egr2 or Egr3 single deficient mice
display weak proliferative responses or relatively normal
responses to TCR stimulation in vitro or viral infection [10,
11, 25, 26]. The severely impaired proliferation of T cells
from CD2-specific Egr2/3/mice demonstrates that Egr2/3
are essential for antigen mediated T cell proliferation [11].
We have now demonstrated that Egr2 and 3 are not required
for the induction of proliferative tolerance, but play a key
role in the control of inflammatory responses of T cells under
tolerogenic conditions.
Our findings of separate mechanisms controlling prolif-
eration and effector function of tolerant T cells open
potential new strategies for modulating T cell function in
tumor immunology and autoimmunity to adjust prolifera-
tion and effector function individually.
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